Literature DB >> 28503254

Management of Potential Long-Term Toxicities in Breast Cancer Patients.

C C O'Sullivan1, K J Ruddy1.   

Abstract

Breast cancer is the most common non-cutaneous malignancy among women, and there are over 3 million breast cancer survivors living in the United States today. Excellent cure rates with modern therapies are associated with substantial toxicities for many women; it is important that health care providers attend to the resulting symptoms and issues to optimize quality of life in this population. In this article, we review management options for potential long term toxicities in breast cancer survivors, with a particular focus on bone health, fertility preservation, premature menopause, cardiac dysfunction, and cognitive impairment.

Entities:  

Keywords:  breast cancer; breast neoplasm; cardiomyopathy; cognitive function; fertility; menopause; osteoporosis; potential long term toxicities; quality of life; review.; toxicities

Year:  2016        PMID: 28503254      PMCID: PMC5424812          DOI: 10.1007/s12609-016-0229-0

Source DB:  PubMed          Journal:  Curr Breast Cancer Rep        ISSN: 1943-4588


  127 in total

1.  Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy.

Authors:  S Salvatore; R E Nappi; M Parma; R Chionna; F Lagona; N Zerbinati; S Ferrero; M Origoni; M Candiani; U Leone Roberti Maggiore
Journal:  Climacteric       Date:  2014-12-16       Impact factor: 3.005

2.  Escitalopram treatment of menopausal hot flashes.

Authors:  Robert R Freedman; Michael L Kruger; Manuel E Tancer
Journal:  Menopause       Date:  2011-08       Impact factor: 2.953

Review 3.  Infertility in reproductive-age female cancer survivors.

Authors:  Jennifer M Levine; Joanne Frankel Kelvin; Gwendolyn P Quinn; Clarisa R Gracia
Journal:  Cancer       Date:  2015-02-03       Impact factor: 6.860

4.  Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer.

Authors:  Kenny A Rodriguez-Wallberg; Kutluk Oktay
Journal:  Oncologist       Date:  2012-09-24

5.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Authors:  Robert Coleman; David Cameron; David Dodwell; Richard Bell; Caroline Wilson; Emma Rathbone; Maccon Keane; Miguel Gil; Roger Burkinshaw; Robert Grieve; Peter Barrett-Lee; Diana Ritchie; Victoria Liversedge; Samantha Hinsley; Helen Marshall
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

6.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Authors:  T J Powles; T Hickish; J A Kanis; A Tidy; S Ashley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

7.  A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.

Authors:  David F Archer; Larry Seidman; Ginger D Constantine; James H Pickar; Sophie Olivier
Journal:  Am J Obstet Gynecol       Date:  2008-12-25       Impact factor: 8.661

8.  Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen.

Authors:  K Oktay; E Buyuk; O Davis; I Yermakova; L Veeck; Z Rosenwaks
Journal:  Hum Reprod       Date:  2003-01       Impact factor: 6.918

9.  Effect of escitalopram on hot flash interference: a randomized, controlled trial.

Authors:  Janet S Carpenter; Katherine A Guthrie; Joseph C Larson; Ellen W Freeman; Hadine Joffe; Susan D Reed; Kristine E Ensrud; Andrea Z LaCroix
Journal:  Fertil Steril       Date:  2012-04-03       Impact factor: 7.490

10.  Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.

Authors:  Nelli Boykoff; Mona Moieni; Saskia Karen Subramanian
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

View more
  2 in total

1.  THE CREATIVE PSYCHOSOCIAL GENOMIC HEALING EXPERIENCE (CPGHE) AND GENE EXPRESSION IN BREAST CANCER PATIENTS: A FEASIBILITY STUDY.

Authors:  Francisco V Muñoz; Linda Larkey
Journal:  Adv Integr Med       Date:  2018-03-13

2.  Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.

Authors:  Yukio Nakamura; Mikio Kamimura; Akio Morikawa; Akira Taguchi; Takako Suzuki; Hiroyuki Kato
Journal:  Ther Clin Risk Manag       Date:  2018-03-14       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.